Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT

Bone Marrow Transplantation
Jan StyczynskiInfectious Diseases Working Party EBMT

Abstract

The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997-2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D- (HR = 1.21; p = 0.044), and R-/D + (HR = 1.21; p = 0.048) in comparison to R-/D- transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R-/D-): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-neg...Continue Reading

References

Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
Aug 17, 2000·The New England Journal of Medicine·J I Cohen
Jun 20, 2008·Statistics in Medicine·Mei-Jie Zhang, Jason Fine
Mar 15, 2013·Bone Marrow Transplantation·Simona Iacobelli, UNKNOWN EBMT Statistical Committee
Jun 19, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jan StyczynskiUNKNOWN Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
Apr 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katayoun Rezvani, Richard E Champlin
Jul 2, 2016·Haematologica·Jan StyczynskiUNKNOWN Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the Europea
Dec 28, 2017·The New England Journal of Medicine·Robert Zeiser, Bruce R Blazar

❮ Previous
Next ❯

Citations

Jan 26, 2021·Annals of Hematology·Michalina KołodziejczakUNKNOWN Infectious Diseases Working Party, European Society for Blood and Marrow Transplantation

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Jacopo MariottiPaolo Corradini
© 2021 Meta ULC. All rights reserved